menu
    • menu
    [{"orgOrder":0,"company":"Pacylex Pharmaceuticals","sponsor":"Canadian Angel Investors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"PCLX-001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pacylex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacylex Pharmaceuticals \/ Canadian Angel Investors","highestDevelopmentStatusID":"5","companyTruncated":"Pacylex Pharmaceuticals \/ Canadian Angel Investors"},{"orgOrder":0,"company":"Sairiyo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cepharanthine DiHCl","moa":"KEAP1-Nrf2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sairiyo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sairiyo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sairiyo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sairiyo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cepharanthine DiHCl","moa":"KEAP1-Nrf2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sairiyo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sairiyo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sairiyo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"225-Ac Vofatamab","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"225-Ac Vofatamab","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Reverb Therapeutics","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2025","type":"Financing","leadProduct":"AMP01","moa":"PD-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Reverb Therapeutics","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Reverb Therapeutics \/ Amplitude Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Reverb Therapeutics \/ Amplitude Ventures"},{"orgOrder":0,"company":"Acuitas","sponsor":"Myeloid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Oligonucleotide","year":"2022","type":"Agreement","leadProduct":"MT-301","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Acuitas","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acuitas \/ Myeloid Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Acuitas \/ Myeloid Therapeutics"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"RP-2119","moa":"Pol-theta","graph1":"Oncology","graph2":"IND Enabling","graph3":"Repare Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"Repare Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FPI-2059","moa":"Neurotensin type-1 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Ipsen","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pharma \/ Ipsen"},{"orgOrder":0,"company":"Defence Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AccuTOX","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Defence Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Defence Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Defence Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"||vasodilators (undefined group)","graph1":"Oncology","graph2":"IND Enabling","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compounds","year":"2023","type":"Inapplicable","leadProduct":"225-Ac FPI-2068","moa":"Alpha-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Bria-Pros+","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2025","type":"Funding","leadProduct":"Bria-PROS-Plus","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BriaCell Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"BriaCell Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"ZW251","moa":"GPC3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zymeworks \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Zymeworks \/ Undisclosed"},{"orgOrder":0,"company":"ProteinQure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"PQ203","moa":"SORT1","graph1":"Oncology","graph2":"IND Enabling","graph3":"ProteinQure","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProteinQure \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"ProteinQure \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BriaCell Therapeutics

                            Canada arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            BriaCell Therapeutics

                            Canada arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bria-PROS-Plus

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : National Cancer Institute

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

                            Details : The proceeds will be used to advance Bria-PROS+, BriaCell’s next-generation personalized off-the-shelf immunotherapy for prostate cancer.

                            Product Name : Bria-PROS-Plus

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 25, 2025

                            Lead Product(s) : Bria-PROS-Plus

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : National Cancer Institute

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ProteinQure

                            Canada arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            ProteinQure

                            Canada arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PQ203

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Clears Phase I, Fast Track For ProteinQure’s PQ203 In US, Canada

                            Details : PQ203 is a novel Peptide Drug Conjugate composed of a peptide targeting the Sortilin receptor, being investigated for the treatment of triple negative breast cancer.

                            Product Name : PQ203

                            Product Type : Peptide-drug Conjugate

                            Upfront Cash : Inapplicable

                            August 07, 2025

                            Lead Product(s) : PQ203

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Zymeworks

                            Canada arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Zymeworks

                            Canada arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZW251

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Clears Zymeworks’ IND For ZW251 GPC3-Targeted ADC

                            Details : ZW251 is a novel glypican-3 (GPC3)-targeted ADC incorporating topoisomerase 1 inhibitor payload, ZD06519, being investigated for the treatment of HCC.

                            Product Name : ZW251

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            July 28, 2025

                            Lead Product(s) : ZW251

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Reverb Therapeutics

                            Canada arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Reverb Therapeutics

                            Canada arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMP01

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Amplitude Ventures

                            Deal Size : $12.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Reverb Therapeutics Raises $12M To Advance Amplify•R™ Platform

                            Details : The financing will support Reverb to advance it's lead AMP01 program blocks PD-1 while delivering endogenous IL-15, a key protein that expands and activates cytotoxic T cells.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            February 19, 2025

                            Lead Product(s) : AMP01

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Amplitude Ventures

                            Deal Size : $12.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sairiyo Therapeutics

                            Canada arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Sairiyo Therapeutics

                            Canada arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cepharanthine Dihydrochloride,Cepharanthine DiHCl

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PharmaTher’s Sairiyo Receives Approval to Start Phase 1 Trial of PD-001 (Cepharanthine)

                            Details : PD-001 (cepharanthine) is an approved, oral, small molecule natural product candidate. It is being evaluated for the treatment of cancer and covid-19 infection.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 19, 2024

                            Lead Product(s) : Cepharanthine Dihydrochloride,Cepharanthine DiHCl

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Zymeworks

                            Canada arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Zymeworks

                            Canada arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZW191

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zymeworks Announces FDA Clearance of IND for ZW191, Novel Folate Receptor-⍺ ADC

                            Details : ZW191 is a novel folate receptor-targeted topoisomerase I inhibitor antibody-drug conjugate. Currently, it is being evaluated in the treatment of tumors such as ovarian, endometrial, and lung cancers.

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            July 22, 2024

                            Lead Product(s) : ZW191

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Zymeworks

                            Canada arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Zymeworks

                            Canada arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZW171

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zymeworks: FDA Clears IND for ZW171 Bispecific Antibody for Cancers

                            Details : ZW171 is a novel 2+1 T-cell targeting bispecific antibody for patients with MSLN-expressing cancers, including ovarian cancer, non-small cell lung cancer, mesothelioma, and other cancers.

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            June 17, 2024

                            Lead Product(s) : ZW171

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            BriaCell Therapeutics

                            Canada arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            BriaCell Therapeutics

                            Canada arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bria-Pros+

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BriaCell Announces Prostate Cancer Candidate Bria-Pros+ and Initiates GMP Manufacturing

                            Details : Bria-Pros+ is a novel off-the-shelf personalized immunotherapy. It is being evaluated in preclinical studies for the treatment of patients with prostate cancer.

                            Product Name : Bria-Pros+

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 02, 2024

                            Lead Product(s) : Bria-Pros+

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Fusion Pharma

                            Canada arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Fusion Pharma

                            Canada arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 225-Ac FPI-2068

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Fusion Pharmaceuticals Announces IND Clearance for FPI-2068, a Jointly Developed Novel Targeted Alpha Therapy

                            Details : [225Ac]-FPI-2068 (FPI-2068) is a targeted alpha therapy (TAT) designed to deliver actinium-225 to various solid tumors that express EGFR and cMET. EGFR and cMET are validated cancer targets that are co-expressed in multiple tumor types.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compounds

                            Upfront Cash : Inapplicable

                            December 04, 2023

                            Lead Product(s) : 225-Ac FPI-2068

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Repare Therapeutics

                            Canada arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Repare Therapeutics

                            Canada arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RP-1664

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhi...

                            Details : RP-1664 demonstrated potent and selective inhibition of PLK4 and synthetic lethality in TRIM37-high tumor cells in preclinical studies. Company expects to initiate clinical trials of RP-1664 in 1H 2024 and RP-3467 in 2H 2024.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 15, 2023

                            Lead Product(s) : RP-1664

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth